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Although retinoic acid (RA) is a potent agent that coordinates inhibition of proliferation with differentiation of many cell types, RA-mediated signaling pathways in osteosarcoma cell differentiation are uncharacterized. In this study, we show that in human U2OS osteosarcoma cells, decreased phosphorylation of RA receptor alpha (RARa) by RA treatment or overexpressing a phosphorylation-defective mutant RARaS77A results in the inhibition of proliferation and induction of differentiation, and that U2OS cells transduced with RARaS77A suppresses tumor formation in nude mice. Moreover, using different human primary osteosarcoma cells and human mesenchymal stem cells for gene expression analysis, we found that either RA or RARaS77A induces many of the same differentiation response pathways and signaling molecules involved in U2OS cell differentiation. In addition, overexpression of the fibroblast growth factor 8f (FGF8f), one of the downstream targets induced by both RA and RARaS77A in U2OS cells, inhibits proliferation and induces expression of osteoblastic differentiation regulators. Hence, these data strongly suggest that RA-suppressed phosphorylation of RARa induces FGF8f expression to mediate differentiation response pathway in U2OS osteosarcoma cells.
Introduction
Osteosarcoma is the most common primary malignant tumor of the bone in humans (Thomas and Kansara, 2006; Clark et al., 2008) , and >80% of osteosarcomas are graded histopathologically as poorly differentiated (Thomas and Kansara, 2006) . Osteosarcoma metastasizes most commonly to the lung (Bacci et al., 2001) . At present, the 5-year survival rate for osteosarcoma is only B60%, and recurrent disease is poorly responsive to further chemotherapy (Clark et al., 2008) . Hence, novel therapies based on noncytotoxic induction of cell differentiation responsive pathways could represent a significant advance.
All-trans retinoic acid (ATRA or RA) is the most potent natural form of vitamin A. The activities of vitamin A in most biological systems are generally attributed to RA and its derivatives (collectively termed 'retinoids'). Numerous experiments and clinical trials have shown that RA and its derivatives are potent agents used for cancer therapy by inducing differentiation of acute myeloid leukemia and various other tumor cells, including breast, melanoma, neuroblastoma and squamous cell cancers (Beere and Hickman, 1993) . Retinoids exert most of their effects by binding to nuclear RA receptors (RARs) and retinoid X receptors (RXRs), which are members of the steroid/thyroid hormone receptor superfamily (Evans, 1988; Chambon, 1996) . RA is a biologically active ligand for these receptors, notably RARs (Evans, 1988; Chambon, 1996) . RARa has two major isoforms, RARa1 and RARa2 (Leroy et al., 1991; Chambon, 1996) . RARa1 (referred as RARa below) is phosphorylated in its B region at serine 77 (S77) by the cyclin-dependent kinase (CDK)-activating kinase (CAK) complex Bastien and Rochette-Egly, 2004) . It is well known that functions of RARa are mediated through heterodimer interaction, protein degradation or phosphorylation regulation (Chambon, 1996; Bastien and Rochette-Egly, 2004) . By overexpressing RARa and phosphorylation-defective RARaS77A in parallel in either RARa mutant or RARaÀ/À cells, we along with others have found that RARaS77A, but not RARa, inhibits proliferation and induces differentiation in either normal or cancer cells (Taneja et al., 1997; Rochette-Egly et al., 2000; Crowe and Kim, 2002; Luo et al., 2007; Wang et al., 2009) . RA-bound RARs and/or RXRs function as transcription factors to induce transactivation by modulating protein-DNA interactions at the RA responsive element (RARE) in the promoters of target genes (Mangelsdorf et al., 1991; Zhang et al., 1992; Chambon, 1996) , although the underlying mechanisms remain to be dissected.
RA has been found to induce osteoblastic differentiation of mouse and rat mesenchymal stem cells (MSCs) (Gazit et al., 1993) and pre-osteoblasts (Traianedes et al., 1993; Benayahu et al., 1994) . RA induces canine osteosarcoma cells to differentiate and exhibit properties of functionally mature osteoblastic cells (Barroga et al., 1999 (Barroga et al., , 2000 Hong et al., 2000a Hong et al., , 2000b , suggesting that RA can restore normal osteogenesis. RA has also been shown to inhibit proliferation of cultured human osteosarcoma cells (Song, 1994) . Moreover, RA regulates expression of human tissue-nonspecific alkaline phosphatase (ALP), which involves modulation of bone formation, through an RARE-like motif in the promoter of tissue-nonspecific ALP in human SAOS-2 osteosarcoma cells (Orimo and Shimada, 2005) . To date, the pathways and mechanisms of RA signaling in mediating osteosarcoma cell differentiation remain unknown.
RARa is a substrate for cyclin-dependent kinase (CDK)-CAK complex, which consists of the catalytic subunit CDK7 (Wu et al., 1994) , the regulatory subunit cyclin H (Fisher and Morgan, 1994) and the assembly factor/targeting subunit MAT1 (Tassan et al., 1995) . The S77 of RARa (RARaS77) is the main residue phosphorylated by CAK . CAK exists in cells as free CAK or as part of the general transcription factor IIH (TFIIH) complex (Nigg, 1996; Fisher, 2005) . Free CAK regulates cell-cycle G 1 progression by phosphorylation activation of CDKs (Nigg, 1996) . Inhibition of CAK phosphorylation of the retinoblastoma tumorsuppressor protein leads cells to exit the cell-cycle G 1 phase (Wu et al., 2001) . On the other hand, TFIIH-containing CAK mediates transcription initiation by phosphorylating the largest subunit of RNA polymerase II (Nigg, 1996; Fisher, 2005) . These studies suggest that changes in CAK phosphorylation of different substrates modulate cell-cycle G 1 exit and transcriptional control. Indeed, CAK hyperphosphorylates RARa in proliferating cancer cells; however, RA decreases CAK activity, induces cell-cycle G 1 arrest and suppresses CAK phosphorylation of RARa, leading to a transition from inhibition of proliferation to differentiation of several types of cancer cells (Crowe and Kim, 2002; Wang et al., 2002; He et al., 2004; Zhang et al., 2004) . These studies indicate that RA links cell-cycle G 1 exit to transcriptional control of cell differentiation by inhibiting CAK phosphorylation of RARa in cancer cells. In this study, we dissect RA signaling pathways of osteosarcoma cell differentiation using both normal and malignant osteogenic cells. Our studies show a novel RA signaling feature of human osteosarcoma cell differentiation, which is mediated by RA-induced loss of CAK phosphorylation of RARa and FGF8f induction.
Results
RA inhibits proliferation and induces cell-cycle G 1 arrest of human osteosarcoma cells We first tested whether RA inhibits proliferation in different human osteosarcoma cell lines as well as in primary osteosarcoma TTL606, TTC444 and CHLA99 cells. The results showed that except TTC444 cells, proliferation was generally inhibited after 3 days of RA treatment in those cells (Figures 1a-e and g ). Such proliferation inhibition was not associated with cell death, which was determined simultaneously by trypan blue exclusion (data not shown). Moreover, cell-cycle analysis determined that RA-inhibited proliferation was associated with cell-cycle G 1 arrest in both U2OS and MG63 cells (Figures 1f and h) . Hence, these data show that inhibition of proliferation in osteosarcoma cells results from RA-induced cell-cycle G 1 arrest.
RA-suppressed RARa phosphorylation is associated with decreased levels of CDK7 and increased expression of differentiation regulators Previous studies have shown that differentiating osteoblastic cells serve as a niche (microenvironment) to mediate granulopoiesis (Taichman and Emerson, 1994; Taichman et al., 1996; Mayack and Wagers, 2008) , whereas RA-induced loss of CAK phosphorylation of RARa has a pivotal role in granulocytic differentiation of hematopoietic precursors (Wang et al., 2002 (Wang et al., , 2006 He et al., 2004; Luo et al., 2007) . We therefore examined whether such CAK-RARa signaling also mediates osteoblastic differentiation. Both western blotting (WB) and reverse transcriptase (RT)-PCR analyses showed that RA treatment decreased the levels of CDK7, which is the catalytic subunit of CAK (Figures 2a and b) . In parallel, RA treatment switched RARa hyperphosphorylation to RARa hypophosphorylation (Figure 2c ). Both reduced CDK7 levels and decreased RARa phosphorylation were associated with the induction of CDK inhibitor p27 Kip1 (p27) (Figures 2d and e) . We also found that in association with the decreased RARa phosphorylation in U2OS cells, the osteoblastic differentiation markers osteopontin (OPN) and osteoprotegerin (OPG) that mediate osteogenesis (Horowitz et al., 2005; Thomas and Kansara, 2006) were induced simultaneously ( Figures  2f and g ). Similar to the observation made by the other group, OPG mRNA was inhibited within 24 h (Figure 2f ) in the presence of RA (Jacobson et al., 2004) . As RARa is a substrate for CAK Wang et al., 2002) and a transcription factor activated by RA, these results suggest that RA-suppressed CAK phosphorylation of RARa links CAK-dependent G 1 arrest to osteoblastic differentiation through transactivation of RA target genes.
Loss of CAK phosphorylation of RARa mimics RA induction of osteoblastic differentiation of U2OS cells S77 is the main RARa residue phosphorylated by CAK . To determine whether RAmediated osteosarcoma cell differentiation results from In contrast to RA-inhibited CDK7 expression (Figures 2a, b and 3i), RARaS77A had no effect on CDK7 expression (Figure 3h ), supporting the notion that RARa hypophosphorylation is a downstream event of RAsuppressed CAK activity. These data show that the loss of CAK phosphorylation of RARa mediates osteosarcoma cell differentiation. Furthermore, RA shows a relatively stronger inhibition of proliferation than does RARaS77A (Figures 3d and e) . Thus, RA may induce a broad effect on inhibition of proliferation than RARa, which is a transcription factor activated by RA to mainly mediate the transactivation of RA target gene expression.
RARaS77A expression in U2OS cells inhibits osteosarcoma formation in nude mice
We next tested whether the effect of RARaS77A on inhibiting proliferation and mediating osteoblastic differentiation of U2OS cells in vitro (Figure 3 ) would lead to inhibit tumor formation in vivo. U2OS or U2OS-RARaS77A cells were subcutaneously injected into BALB/c nude mice. After 7 weeks, 10 of 15 mice injected with U2OS cells showed a tumor-like formation (Figure 4a ), which was determined to be an osteosarcomalike tissue by hematoxylin and eosin staining ( Figure 4d ). In contrast, no tumor was found in 15 mice injected with U2OS-RARaS77A cells (Figure 4b ). The established tumors in mice disappeared after (1) the loss of RARa phosphorylation by CAK inhibits osteosarcoma formation and (2) RA suppresses osteosarcoma cell proliferation.
RARaS77A mimics the effect of RA on inducing signaling pathways of osteosarcoma cell differentiation As RARaS77A mimics RA induction of osteoblastic differentiation and inhibits osteosarcoma formation ( Figures 3 and 4) , we investigated the potential targets of RA and RARaS77A in U2OS cells using DNA microarray analysis. It is known that cancer cell differentiation requires cell-cycle exit, by which at least two waves of signaling events are involved: induction of cell-cycle arrest and transition into transactivation of target genes that regulates differentiation (Studzinski and Harrison, 1999; Zhu and Skoultchi, 2001) . As RAinduced cancer cell differentiation usually takes 3-7 days depending on the different cell types (Taneja et al., 1997; Wang et al., 2002 Wang et al., , 2006 Zhang et al., 2004) , we assessed changes in gene expression from the induction of osteosarcoma cell-cycle G 1 arrest to differentiation induced by RA or S77A (Figures 1-3 ) in parallel. Therefore, instead of using one time point of duplicate RNA samples in microarray analysis, a single RNA sample was used for each progressive time point at 3 and 7 days, respectively; blank U2OS cells were used as control. The results (see 'Detailed Analysis of Microarray Data' in Supplementary Material) showed that among 38 000 genes tested, >7000 genes were upregulated (X2-1000-fold) in response to RA treatment and RARaS77A expression at 3 and 7 days, respectively (Figures 5a and b) . Among them, RA and RARaS77A shared B4000 of those upregulated target genes ( Figure 5b ). Moreover, RA and RARaS77A induces many of the same signaling pathways involved in regulating osteoblastic differentiation, including cell adhesion molecules, extracellular matrix-receptor interaction, cell cycle, JAK-STAT (Janus kinase-signal transducers and activators of transcription) signaling pathway, mitogen-activated protein kinase (MAPK) signaling pathway, transforming growth factor-b signaling pathway and WNT signaling pathway (Figure 5c ). In addition, both RA stimulus and RARaS77A expression induce the hematopoietic lineage pathway and B-cell receptor signaling pathway (Figure 5c ), supporting the notion that osteoblastic differentiation simultaneously mediates hematopoiesis (Li and Li, 2006) . On the other hand, >4000 genes were inhibited by RA stimulus and RARaS77A expression (Supplementary Figures 1A and B) . Among them, RA and RARaS77A shared >2000 of those downregulated target genes (p2-1600-fold) (Supplementary Figure 1B) . Several similar pathways that are not directly involved in osteogenesis, such as neuroactive ligand-receptor interaction, long-term depression and human immunodeficiency virus-induced T-cell apoptosis, were inhibited by either RA treatment or RARaS77A expression at 3 and 7 days, respectively (Supplementary Figure 1C) . 
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To check whether RA-decreased RARa phosphorylation represents a general signaling event involved in normal osteoblastic development and osteosarcoma transformation, we performed DNA microarray to delineate RA signaling pathways using human MSCs (hMSCs), primary osteosarcoma TTC444 and TTU606 cells, as well as UT2 cells in parallel to U2OS cells treated with RA or expressing RARaS77A. The results showed that some important pathways inhibited in different osteosarcoma cells compared with hMSCs, including extracellular matrix-receptor interaction, hematopoietic lineage, cell communication and focal pathways, were activated by either RA treatment or RARaS77A expression in U2OS cells (data not shown). Many of the same signaling molecules that were either downregulated or upregulated in U2OS cells compared with hMSCs were correspondingly upregulated or downregulated by either RA stimulus or RARaS77A expression, respectively (Supplementary Figure 2A and B vs C and D). Among them, 11 genes (marked with *) were also inhibited in those different primary osteosarcoma cells compared with hMSCs, similar to U2OS cells in the absence of either RA stimulus or RARaS77A expression compared with hMSCs ( Supplementary  Figure 2A) . Interestingly, all these 11 genes have critical roles in mediating both osteoblastic differentiation and hematopoietic cell development. Taken together, these data indicate that diminution of RARa phosphorylation, whether by RA treatment or RARaS77A overexpression, modulates similar pathways regulating osteoblastic differentiation.
We also found that many important signaling molecules, including transcription factors, cytokines and regulatory molecules, were induced in U2OS cells by RA stimulus and RARaS77A expression (Figures  6a-c) . Either RA treatment or RARaS77A expression induced many of the same key factors involved in mediating MAPK, transforming growth factor-b and WNT differentiation response pathways, including FGF8, BMP8a and WNT8b (Figures 6d-f) . By using RT-PCR to evaluate several upregulated genes determined in array analysis (Figure 6 ), the results (Supplementary Figure 3 ) confirmed that both RA and RARaS77A induced cyclin C, BMP8a, RAP1A (data not shown in Figure 6c , upper panel), FGF8 and HOXA5 (induced by RA only). Moreover, we found that with seven probes for detecting the RARa gene in the array chip, the levels of RARa basically remain the same in U2OS cells transduced with RARaS77A, showing an average change of 1.3-fold compared with Osteosarcoma cell differentiation P Luo et al controls. These array results are similar to the data from RT-PCR (Figure 3h ), supporting the notion that the function of RARa is mainly mediated posttranslationally, for example, regulation of RARa phosphorylation (Figures 2c and 3) . On the other hand, we also observed a few inconsistencies by comparing some microarray data with both RT-PCR and WB results (see 'A Few Inconsistencies between Array Data and RT-PCR/WB Results' in Supplementary Material). Taken together, these data suggest that RARa hypophosphorylation mimics RA effect on inducing signaling pathways to mediate osteosarcoma cell differentiation, and that CAK phosphorylation of RARa is inhibited in RAinduced osteosarcoma cell differentiation.
RA-mediated RARa hypophosphorylation induces FGF8f expression
The above-mentioned data show that U2OS cell differentiation mediated by either RA stimulus or RARaS77A expression (Figures 1-4) is associated with the induction of FGF8 expression (Figure 6f ; Supplementary Figure 2A) . FGF8 is known to have an important role in osteoblastic development and bone formation (Ornitz and Marie, 2002) . This suggests that the RA-dependent loss of CAK phosphorylation of RARa induces FGF8 to regulate osteosarcoma cell differentiation. The human FGF8 gene encodes four alternatively spliced polypeptide products, including FGF8f, FGF8e, FGF8b and FGF8a (Gemel et al., 1996) , the distinct functions of which in mediating cell differentiation remain unknown. By using different PCR primers specific for either total FGF8 mRNA or different FGF8 splice variants (Figure 7a) , we first examined which FGF8 isoform(s) could be induced by RA and/or RARaS77A in U2OS cells. We found that FGF8f and FGF8b mRNAs, but not FGF8a or FGF8e mRNAs, were expressed in U2OS cells (Figure 7b ). FGF8f was induced with either RA treatment or RARaS77A expression (Figures 7b and c) . Interestingly, FGF8 antibodies (sc-7916; Santa Cruz Biotechnology, Santa Cruz, CA, USA) only recognized a major 30-kDa protein, corresponding to the molecular mass of FGF8f (Gemel et al., 1996) on SDS-PAGE (Figure 7d ), and Figure 4) . RT-PCR analysis showed that FGF8f mimicked the RA effect of inducing expression of differentiation marker genes, including OPN, OPG, Runx2 and osteocalcin ( Figures  8c and d) . In U2OS cells treated with RA or transduced by FGF8f, the levels of both FGF8f and OPN proteins were upregulated (Figures 8e and f) . Next, by using small interfering RNA (siRNA) and antibody neutralization, we verified the role of FGF8f in osteoblastic differentiation. Owing to the special structure of the FGF8 isoforms (Figure 7a ), we cannot design either siRNA or antibody against FGF8f specifically. As FGF8f is the main isoform induced by RA or RARaS77A in U2OS cells (Figures 7b-e Zhang et al., 2004) . We find in this study that RA inhibits cell proliferation by inducing G 1 arrest in osteosarcoma cells (Figure 1) , which is associated with decreased CDK7 expression, decreased RARa phosphorylation and upregulated expression of osteoblastic differentiation regulators (Figure 2 ). These results suggest that RA coordinates inhibition of proliferation with induction of osteosarcoma cell differentiation by suppressing CAK phosphorylation of RARa. Further studies in U2OS cells show that overexpression of phosphorylation-defective RARaS77A mimics the effects of RA on inhibition of cell proliferation, suppression of osteosarcoma formation in nude mouse and induction of expression of osteoblastic differentiation marker genes, as well as differentiation response pathways (Figures 3-7) . Moreover, overexpression of FGF8f, a downstream target of RARaS77A and a key signaling molecule of the MAPK pathways, mimics the effects of either RA or RARaS77A on inhibiting proliferation and inducing differentiation of U2OS cells (Figure 8 ). Hence, these data indicate that RA-dependent loss of CAK phosphorylation of RARa and induction of FGF8f represent key signaling events that coordinate G 1 arrest with differentiation of osteosarcoma cells. However, RA isomer formation, or 9cRA conversion, or other RARa agonist may also be involved in the regulation of RARa/RXRa-mediated osteosarcoma cell differentiation through similar or different signaling pathways. It is therefore important, in future studies, to investigate such possible mechanistic correlations with decreased CAK phosphorylation of RARa in coordinating CAK-dependent G 1 arrest with RARa-mediated cancer cell differentiation. At present, the mechanisms by which RARa transactivates FGF8 are unknown. Previous studies have shown that RA induces expression of FGF8a isoform while suppressing FGF8b in LNCaP cells (Brondani and Hamy, 2000) . The FGF8 promoter contains functional binding sites of RARa, whereas RARa interacts with these DNA binding sites, leading to induction of CAT activity (Brondani et al., 2002) . According to the current model of gene regulation by retinoids (Bastien and Rochette-Egly, 2004 ), unliganded and DNA-bound retinoid receptors repress transcription through the recruitment of corepressors; whereas ligand-induced conformational changes in the receptors cause dissociation of corepressors and recruitment of coactivators (Melnick and Licht, 1999; Aranda and Pascual, 2001; Bastien and Rochette-Egly, 2004) . Such chromatin remodeling leads to decompaction of repressive chromatin and facilitating the recruitment of TFIIH complexes to the promoter of target genes to initiate Osteosarcoma cell differentiation P Luo et al transcription (Bastien and Rochette-Egly, 2004) . We find that both RA stimulus and RARaS77A expression induces FGF8f expression (Figures 6-8) , which mediates osteoblastic differentiation (Figure 8) . Therefore, these studies suggest that the loss of CAK phosphorylation of RARa transactivates FGF8f to mediate osteoblastic differentiation by recruiting coactivators/transcriptional machinery to the FGF8 promoter.
The roles of FGF8f signaling and MAPK pathways in osteoblastic differentiation FGF8 is one of most extensively studied FGF family member that modulates a balance between proliferation and differentiation (Mattila and Harkonen, 2007) . Although many studies have shown that FGF8 regulates osteoblast development and bone formation (Ornitz and Marie, 2002; Jackson et al., 2006) , the distinct physiological functions of different FGF8 isoforms in such regulations are unknown. We find that both RA and RARaS77A induce FGF8f expression in U2OS cells (Figure 6f ; Supplementary Figure 2A , 7B-E and 8C-E). Overexpression of FGF8f in U2OS cells mimics the effects of either RA or RARaS77A on inhibiting proliferation and inducing expression of osteoblastic differentiation regulators, including OPN, Runx2 and osteocalcin (Figures 3, 8) . Moreover, we also find that RA-induced loss of CAK phosphorylation of RARa and FGF8f induction are involved in osteoblastic development of hMSCs (data not shown). How is the FGF8f signal transduced in RA-induced osteoblastic differentiation? Molecular evidence has shown that a large proportion of FGF signals are transduced through activation of the MAPK pathways, by which the binding of FGF to FGF receptors causes FGFR dimerization and subsequent autophosphorylation of intrinsic tyrosine residues. This, in turn, leads to the downstream activation of distinct MAPK pathways (Jackson et al., 2006) . Previous studies have shown that RA mediates MAPK pathways in mediating both normal and malignant cell differentiation (Hoffman et al., 2003; Wang, 2005) . Our data show that both RA stimulus and RARaS77A expression induce FGF8f expression and MAPK signaling pathways (Figures 5-8) . Hence, our studies suggest that the induction of FGF8f mediated by RA-RARa signaling leads to osteoblastic differentiation by activation of MAPK pathways.
RA-RARa-FGF8f signal transduction coordinates with multiple classes of the MAPK, BMP and WNT pathways in mediating osteobalstic differentiation The balance between cell division and cell differentiation is maintained by the precise coordination of multiple pathways. Previous studies have shown that FGF (Ornitz and Osteosarcoma cell differentiation P Luo et al Marie, 2002) , BMP (Chen et al., 2004) and WNT pathways (Liu et al., 2008) are important signaling networks coexisting within bone cells during development and carcinogenesis. The FGF-PI3K-AKT signaling pathway and the canonical WNT signaling pathway cross talk at glycogen synthase kinase-b during carcinogenesis (Katoh, 2006) , whereas FGF and BMP share MAPKdependent pathways in regulating osteogenesis (Franceschi and Xiao, 2003) . We find that upon osteoblastic differentiation induced by RA-RARa-FGF8f, several important MAPK, BMP and WNT signaling pathways are simultaneously activated ( Figure 5 ). Many key regulators involved in these signaling pathways are correspondingly upregulated by either RA stimulus or RARaS77A expression, including FGF8f, phosphatidylinositol 3-kinase C3, WNT8b, d-catenin, BMP8a, interleukin-8 and NCOA3 (Figures 6-8) . Therefore, these data suggest that either RA-or RARaS77A-induced FGF8f signal transduction cooperate with MAKP, BMP and WNT pathways to synchronize osteoblastogenesis (Figure 9 ), although the signal transductions and mechanisms among these networks remain to be dissected. In summary, our studies suggest that RA-mediated loss of CAK phosphorylation of RARa induces FGF8f to activate MAPK pathways, leading to collaboration with BMP and/or WNT signaling networks to mediate osteosarcoma cell differentiation (Figure 9) . A more precise assessment of FGF8f function in osteoblastic differentiation may be undertaken in mice by xenografting human osteosarcoma cells or hMSCs expressing RARaS77A or FGF8f. Such studies should foster the integration of RA signaling into osteosarcoma cell differentiation, providing the basis for devising effective differentiating therapies against osteosarcoma.
Materials and methods

Cell culture
Human osteosarcoma U2OS, MG63, SAOS-2 cell lines (American Type Culture Collection, Manassas, VA, USA), UT2 cells (derived from the second human-mouse xenotransplantation of U2OS cell-formed osteosarcoma tissues), as well as human primary osteosarcoma cells (CHLA Pathology Tissue Bank, Los Angeles, CA, USA), including TTC444, CHLA99 and TTTU606, were cultured as described before (Wu et al., 2001) . hMSCs were purchased from TUCGT (Tulane University Center for Gene Therapy) under material transfer agreement. By following the standard protocols provided by TUCGT, hMSCs were cultured in complete maintenance medium. ATRA (Sigma, St Louis, MO, USA) was dissolved in ethanol. ATRA (1 mM) or vehicle (0.1% ethanol) was used in the experiments.
Lentiviral plasmid construction, virion production and transduction The RARaS77A cDNA (Luo et al., 2007) and FGF8f cDNA (OriGene, Rockville, MD, USA) were cloned into pCCL-cMNDU3c-X2-PKG-EGFP lentiviral vector (Luo et al., 2007) . Virion production, titration and transduction were performed as described previously (Luo et al., 2007) . RA was added after 12 h of S77A transduction in RA-related experiments.
Proliferation and cell-cycle analysis Cell replication (Luo et al., 2007) and cell-cycle analysis (Wang et al., 2002) were performed as described before.
Western blotting WB was performed as described previously (Wang et al., 2002) . All antibodies were obtained from Santa Cruz Biotechnology.
Reverse transcription-PCR analysis RT-PCR and RNA normalization were performed as described previously (Luo et al., 2007) .
Constitution of UT2 cells U2OS cells (1 Â 10 7 ) were injected subcutaneously into the shoulder region of BALB/c nude mice (The Jackson Laboratory, Bar Harbor, ME, USA). The established osteosarcoma tissues were harvested for UT1 cell constitution and second mouse xenotransplantation. The established UT2 osteosarcoma tissues were dissociated as small pieces to release single cells. Larger tumor aggregates were aspirated away the next day, and the adherent cells were cultured until desired UT2 populations were reached.
Measurement of intracellular ALP activities
Triplicate 1 Â 10 4 cells of each sample were washed with phosphate-buffered saline and lysed in 0.5 ml of 0.2% Triton X-100. Alkaline Phosphatase Assay Kit (Bioassay Systems, Hayward, CA, USA) was used to determine ALP activities by following the manufacturer's instructions.
Xenografts of human osteosarcoma and RA treatment U2OS or U2OS-RARaS77A cells were xenografted subcutaneously into nude mice. Tumor formation/volume was monitored until reaching B0.6 cm 3 . The mice were then injected intraperitoneal with RA (20 mg/kg) or vehicle (1:1:8, v/v Cremophor EL:Ethanol:Saline) for 18 days with interval of 24 h at every 6 days.
Microarray analysis of osteosarcoma cells and hMSCs HGU133 plus-2 arrays (450 000 probe sets; 438 000 genes) obtained from Affymetrix (Santa Clara, CA, USA) were used in the studies. U2OS, UT2, hMSCs, as well as primary osteosarcoma cells TTC444 and TTU606 (480% tumor cells) were subjected to array analysis. U2OS cells were either treated with RA or vehicle or transduced with RARaS77A. hMSCs were cultured in complete maintenance medium for 7 days. RNAs were isolated, purified and quantified. Experimental Figure 9 Hypothetical network of differentiation response pathways coordinated by RA-RARa-FGF8f signal transduction during osteoblastic differentiation.
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RNA interference siRNA against FGF8 (sc-39458; Santa Cruz Biotechnology) or a nontargeting control siRNA (sc-37007; Santa Cruz Biotechnology), complexed with Lipofectamin (Invitrogen, Carlsbad, CA, USA) following the manufacturer' instructions, were applied to U2OS cells grown in RPMI with 10% fetal bovine serum in 6-well plates, to yield a final concentration of 30 nmol/l. Blocking peptides of FGF8 antibody (sc-27144P; Santa Cruz Biotechnology) were used (100 ng/ml) as additional control. After 8 h of transfection, cells were cultured in fresh RPMI. Cells were collected after 72 h for proliferation analysis by cell count or for assessing gene expression by RT-PCR.
Antibody neutralization U2OS cells treated with RA or transduced with RARaS77A or FGF8f in 12-well plates were exposed to 100 ng/ml FGF8 antibodies (sc-27144; Santa Cruz Biotechnology). Blocking peptide against FGF8 antibody was used as control. After 4 days of treatment, cell proliferation was analyzed by cell account.
Hematoxylin and eosin staining Tumor tissues were harvested, fixed in 10% buffered formalin and embedded in paraffin. Hematoxylin and eosin staining was performed at the Childrens Hospital Los Angeles Pathology Core (Los Angeles, CA, USA).
